12:00 AM
 | 
Jan 09, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Subcutaneous Cinryze: Phase II data

Top-line data from an open-label Phase II trial in 12 patients with HAE showed that twice-weekly 1,000 and 2,000 U doses of subcutaneous Cinryze formulated with rHuPH20 led to higher maximum levels and greater systemic exposure of functional and antigenic C1...

Read the full 194 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >